Safe and Effective Medicines for Children - Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act (Paperback)

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

General

Imprint:	National Academies Press
Country of origin:	United States
Release date:	October 2012
First published:	2012
Authors:	Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) • Board on Health Sciences Policy • Institute of Medicine
Editors:	Marilyn J. Field • Thomas F. Boat
Dimensions:	229 x 152 x 26mm (L x W x T)
Format:	Paperback
Pages:	432
ISBN-13:	978-0-309-22549-6
Categories:	Books > Medicine > Clinical & internal medicine > Paediatric medicine > General Books > Medicine > Other branches of medicine > Pharmacology > General
LSN:	0-309-22549-3
Barcode:	9780309225496

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!